Gressami 200mg Tablet contains Amisulpride, an atypical antipsychotic agent primarily indicated for the treatment of schizophrenia and other psychotic disorders. Amisulpride acts selectively on dopamine D2 and D3 receptors, exhibiting both antipsychotic and antidepressant properties depending on the dosage. At low doses, it preferentially blocks presynaptic dopamine autoreceptors, enhancing dopaminergic transmission, which may alleviate negative symptoms and depressive features. At higher doses, it antagonizes postsynaptic dopamine receptors, reducing positive symptoms such as hallucinations and delusions. Gressami 200mg is typically prescribed for acute and chronic management of schizophrenia, including positive and negative symptomatology. The tablet should be administered orally, with dosage individualized based on clinical response and tolerability. Common adverse effects may include extrapyramidal symptoms, hyperprolactinemia, sedation, and gastrointestinal disturbances. Caution is advised in patients with a history of cardiac arrhythmias, epilepsy, or renal impairment. Regular monitoring of clinical status, metabolic parameters, and potential side effects is recommended during therapy. Gressami 200mg should be used under strict medical supervision, and abrupt discontinuation should be avoided to prevent withdrawal symptoms or relapse. It is contraindicated in patients with hypersensitivity to Amisulpride or other components of the formulation.